Cutting reimbursement for 24 drugs could save Medicare $1.6 billion

Article Overview

This article covers a Medicare reimbursement policy issue involving physician-administered drugs and a government study estimating potential savings if payments were reduced. It is relevant to coding, reimbursement, and compliance professionals who track federal payment policy, HCFA/CMS-related administrative actions, and congressional oversight of drug pricing. The article also places the issue in the context of Medicare payment methods for administered drugs and the broader policy debate over drug reimbursement levels.